{"id":5108,"date":"2026-03-13T11:18:55","date_gmt":"2026-03-13T11:18:55","guid":{"rendered":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/?p=5108"},"modified":"2026-03-13T11:19:00","modified_gmt":"2026-03-13T11:19:00","slug":"il31-eczema-treatment","status":"publish","type":"post","link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/il31-eczema-treatment\/","title":{"rendered":"Targeting IL-31 in Eczema: New Treatments for Chronic Itch"},"content":{"rendered":"\n
Living with eczema often means dealing with relentless itch that can interfere with sleep, concentration, and emotional wellbeing. While traditional treatments focus on reducing inflammation, soothing the skin, and managing flare-ups, many patients still struggle with persistent itching that affects daily life. This has led researchers to search for new ways to target the root causes of chronic itch.<\/p>\n\n\n\n
One promising discovery is the role of a cytokine called IL-31. This molecule is heavily involved in signalling the nerve cells in the skin that trigger the sensation of itch. High levels of IL-31 are linked with more severe itching in eczema, which explains why some patients continue to experience discomfort even when inflammation is controlled.<\/p>\n\n\n\n
Understanding IL-31 has opened the door to therapies that directly interfere with these itch signals. By targeting the pathways activated by IL-31, new treatments aim to reduce chronic itch at its source rather than only treating the visible skin symptoms. This approach represents a shift towards more precise and effective eczema management.<\/p>\n\n\n\n
Clinical studies on IL-31 inhibitors and related therapies are showing promising results. Patients receiving these treatments report significant relief from persistent itch, improved sleep, and better overall quality of life. For those who have struggled with conventional therapies, IL-31-targeted treatments offer hope for long-lasting control over eczema-related itch.<\/p>\n\n\n\n
What Is IL-31?<\/strong><\/h2>\n\n\n\n
IL-31 is a protein in the immune system known as a cytokine. Cytokines are signalling molecules that allow immune cells to communicate and coordinate responses, particularly during inflammation or allergic reactions.<\/p>\n\n\n\n
In people with eczema, IL-31 levels are often elevated in the skin, contributing directly to the sensation of itch. By binding to its receptor on nerve endings, IL-31 sends strong signals to the brain that trigger the urge to scratch.<\/p>\n\n\n\n
This mechanism helps explain why some patients experience chronic, persistent itching even when other signs of eczema, such as redness or swelling, are controlled. Targeting IL-31 offers a potential way to reduce itch at its source rather than simply treating surface symptoms.<\/p>\n\n\n\n
The Role of IL-31 in Eczema<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\n
Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition characterised by redness, dryness, and intense itching. While conventional treatments aim to control inflammation, they do not always fully relieve the discomfort associated with itch. Research has highlighted the role of interleukin-31 (IL-31) as a key mediator that links the immune system to the nervous system. Essentially, IL-31 translates immune activity into the sensation of itch, making it a promising target for therapies aimed at reducing scratching and improving quality of life.<\/p>\n\n\n\n
\n
IL-31 as a Neural-Immune Link:<\/strong> IL-31 acts as a messenger between immune cells and nerve endings in the skin. This communication triggers the itch sensation, even in areas where inflammation may be mild.<\/li>\n\n\n\n
Beyond Inflammation Control: <\/strong>Traditional eczema treatments focus on reducing immune-mediated inflammation. Targeting IL-31 could directly address itch, offering relief even when inflammation persists.<\/li>\n\n\n\n
Potential for Targeted Therapy:<\/strong> By inhibiting IL-31 or its receptor, new treatments may reduce scratching behaviour, preventing further skin damage and improving long-term outcomes.<\/li>\n\n\n\n
Improving Patient Comfort:<\/strong> Managing itch through IL-31 pathways can significantly enhance patient comfort and adherence to therapy, as persistent itch is often the most distressing symptom of eczema.<\/li>\n<\/ul>\n\n\n\n
In conclusion, IL-31 plays a central role in converting immune activity into the physical sensation of itch in eczema. Targeting this pathway offers a promising approach to relieve discomfort, complementing traditional anti-inflammatory treatments and improving overall disease management.<\/p>\n\n\n\n
Why Chronic Itch Is a Major Concern<\/strong><\/h2>\n\n\n\n
Persistent itching in eczema can have far-reaching effects on a patient\u2019s daily life. It often disrupts sleep, making it difficult to feel rested, reduces concentration and productivity, and can contribute to emotional challenges such as anxiety, frustration, or depression. Over time, this constant discomfort can significantly lower quality of life, affecting both personal and professional activities.<\/p>\n\n\n\n
Scratching in response to itch further damages the skin barrier, increasing the risk of infections and worsening eczema symptoms. This creates a self-perpetuating \u201citch-scratch cycle,\u201d where inflammation and discomfort feed into each other, making the condition more difficult to control. Even minor irritation can escalate, leading to more severe flares and chronic skin changes.<\/p>\n\n\n\n
Because of this cycle, managing chronic itch has become a central focus in eczema care. Addressing the underlying causes, such as elevated IL-31, can help break the cycle, reduce persistent scratching, and promote healing. Effective itch control not only improves skin health but also enhances sleep, mood, and overall quality of life for patients living with eczema.<\/p>\n\n\n\n
How IL-31 Activates Nerve Pathways<\/strong><\/h2>\n\n\n\n
IL-31 exerts its effects by binding to a specific receptor called IL-31RA, which is found on peripheral sensory neurons in the skin. When IL-31 attaches to this receptor, it activates these nerve cells, triggering signals that travel to the spinal cord and then to the brain. This process directly generates the sensation of itch.<\/p>\n\n\n\n
This mechanism helps explain why some patients with only mild visible inflammation may still experience intense itching. In these cases, the itch is driven primarily by nerve activation rather than by obvious skin changes like redness or swelling.<\/p>\n\n\n\n
By targeting IL-31 or its receptor, new therapies aim to interrupt this signalling pathway. Blocking IL-31-mediated nerve activation can reduce chronic itch at its source, offering relief even when traditional anti-inflammatory treatments are insufficient.<\/p>\n\n\n\n
IL-31 in Other Skin Conditions<\/strong><\/h2>\n\n\n\n
Although IL-31 is most extensively studied in eczema, elevated levels of this cytokine have also been observed in other inflammatory skin disorders. Conditions such as prurigo nodularis, where patients experience intense nodular lesions and severe itch, and certain forms of psoriasis, show increased IL-31 activity.<\/p>\n\n\n\n
Recognising IL-31\u2019s role across multiple skin diseases highlights its importance as a driver of chronic itch. By understanding these mechanisms, researchers can develop therapies that target IL-31 not just in atopic dermatitis, but in a broader range of itch-related conditions.<\/p>\n\n\n\n
IL-31-targeted treatments therefore have the potential to provide relief for patients who struggle with persistent itching in different dermatological disorders. This expands the possibilities for more effective, tailored therapies that address the underlying cause of itch rather than just its symptoms.<\/p>\n\n\n\n
Traditional Approaches to Managing Eczema Itch<\/strong><\/h2>\n\n\n\n
Conventional treatments for eczema focus primarily on reducing inflammation and soothing the skin. Common approaches include topical corticosteroids, which help control flare-ups; calcineurin inhibitors, which modulate immune activity; and emollients or moisturisers, which restore the skin barrier and prevent dryness. Antihistamines are sometimes used to relieve itch, though their effectiveness in eczema is often limited.<\/p>\n\n\n\n
While these therapies can improve skin appearance and reduce inflammation, they do not directly target the IL-31 pathway responsible for signalling itch to the nervous system. As a result, many patients continue to experience persistent itching even when visible symptoms are controlled.<\/p>\n\n\n\n
This limitation has driven the development of new treatments that specifically block IL-31 or its receptor, offering a more targeted approach for managing chronic itch. By addressing the underlying itch pathway, these therapies aim to provide relief where traditional treatments may fall short.<\/p>\n\n\n\n
Why New Therapies Are Needed<\/strong><\/h2>\n\n\n\n
For many patients with eczema, itch remains the most persistent and bothersome symptom, even after inflammation and flare-ups are controlled. This ongoing discomfort can affect sleep, daily activities, and overall quality of life. Traditional anti-inflammatory treatments often fail to fully address this problem, leaving a significant unmet need for more effective solutions.<\/p>\n\n\n\n
Research has therefore focused on therapies that directly target the pathways responsible for itch. IL-31 has emerged as a prime candidate because of its central role in transmitting chronic itch signals from the skin to the nervous system.<\/p>\n\n\n\n
By developing treatments that block IL-31 or its receptor, scientists aim to interrupt the itch at its source rather than just managing the symptoms. These targeted approaches offer hope for patients who continue to struggle with persistent itching despite conventional eczema therapies.<\/p>\n\n\n\n
Monoclonal Antibodies Against IL-31<\/strong><\/h2>\n\n\n\n
Monoclonal antibodies are highly specialised, laboratory-engineered proteins that target specific molecules with precision. In eczema, some of these antibodies are designed to focus on IL-31 or its receptor, IL-31RA, both of which play a central role in driving chronic itch. By targeting this pathway, these therapies aim to address the root cause of persistent itching rather than just treating surface inflammation.<\/p>\n\n\n\n
By binding to IL-31 or blocking its receptor, these treatments prevent the cytokine from activating nerve endings in the skin. This stops the itch signals from reaching the brain, effectively interrupting the persistent itch-scratch cycle that can worsen eczema over time.<\/p>\n\n\n\n
Clinical studies have shown that IL-31-targeted monoclonal antibodies can significantly reduce chronic itch, improve sleep quality, and enhance overall daily comfort. For patients who continue to struggle despite conventional treatments, these therapies offer a promising and more precise approach to long-term relief and improved quality of life.<\/p>\n\n\n\n
Nemolizumab: A Promising IL-31 Inhibitor<\/strong><\/h2>\n\n\n\n
Nemolizumab is an emerging therapy that specifically targets interleukin-31 (IL-31), a key driver of itch in eczema. Clinical trials have demonstrated that blocking IL-31 with nemolizumab can significantly reduce itch intensity in patients with moderate-to-severe atopic dermatitis. By addressing the neural pathway of itch directly, this therapy provides relief even when skin inflammation persists, offering benefits beyond conventional anti-inflammatory treatments.<\/p>\n\n\n\n
\n
Effective Itch Reduction:<\/strong> Clinical studies show that nemolizumab significantly decreases the frequency and intensity of itching, providing rapid symptom relief for many patients.<\/li>\n\n\n\n
Improved Sleep and Daily Comfort:<\/strong> Reducing itch helps patients sleep better and engage in daily activities more comfortably, addressing one of the most disruptive aspects of eczema.<\/li>\n\n\n\n
Benefits Independent of Visible Skin Changes:<\/strong> Patients often experience improvements in quality of life before noticeable improvements in skin appearance, highlighting the unique advantage of targeting IL-31.<\/li>\n\n\n\n
Complementary to Traditional Therapies:<\/strong> Nemolizumab works alongside anti-inflammatory treatments, allowing a dual approach that tackles both inflammation and the neural sensation of itch.<\/li>\n<\/ul>\n\n\n\n
In conclusion, nemolizumab represents a promising advance in eczema management by targeting IL-31. By directly reducing itch, it improves patient comfort, sleep, and overall quality of life, complementing traditional treatments that primarily address inflammation.<\/p>\n\n\n\n
Safety and Side Effects<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\n
IL-31-targeted therapies are generally well tolerated, with most patients experiencing only mild or manageable side effects. The most commonly reported issues include injection site reactions such as redness, swelling, or mild discomfort, and occasional transient infections that typically resolve without intervention. These side effects are usually short-lived and do not interfere with the overall benefits of treatment.<\/p>\n\n\n\n
One of the advantages of these therapies is their precision. By specifically blocking the IL-31 itch-signalling pathway, they avoid the broader immunosuppressive effects seen with systemic corticosteroids or other general immune-modulating treatments. This targeted action helps preserve the immune system\u2019s normal function while effectively reducing chronic itch.<\/p>\n\n\n\n
Ongoing clinical monitoring and follow-up care ensure that any adverse reactions are identified and managed promptly. For many patients, the combination of a favourable safety profile, minimal systemic impact, and significant relief from persistent itching makes IL-31-targeted therapies a promising and practical option for long-term eczema management.<\/p>\n\n\n\n
Combining IL-31 Inhibitors with Other Treatments<\/strong><\/h2>\n\n\n\n
In clinical practice, IL-31-targeted therapies are often used alongside other eczema treatments to provide comprehensive symptom control. While the IL-31 inhibitor specifically reduces chronic itch, additional therapies such as topical corticosteroids, calcineurin inhibitors, or systemic biologics may still be necessary to manage active inflammation in more severe cases.<\/p>\n\n\n\n
This combined approach addresses both the underlying immune response and the persistent itch, helping to break the itch-scratch cycle while promoting skin healing. By targeting multiple pathways, patients can achieve better overall control of their eczema symptoms.<\/p>\n\n\n\n
For many patients, integrating IL-31 inhibitors with traditional or systemic treatments enhances daily comfort, improves sleep, and supports a higher quality of life. Tailoring therapy combinations to individual needs allows dermatologists to provide personalised and effective eczema management.<\/p>\n\n\n\n
While IL-31-targeted therapies are primarily being studied for atopic dermatitis, research suggests they could benefit a wider range of chronic itch conditions. Disorders such as prurigo nodularis, chronic urticaria, and itch associated with kidney or liver disease (renal and hepatic pruritus) often involve similar neural-immune pathways. By addressing IL-31, these therapies have the potential to relieve itch across multiple conditions, offering a novel approach where traditional treatments may be limited.<\/p>\n\n\n\n
\n
Broader Applications in Dermatology:<\/strong> IL-31 plays a role in the sensation of itch beyond eczema, making it a potential therapeutic target for a variety of chronic pruritic disorders.<\/li>\n\n\n\n
Prurigo Nodularis and Chronic Urticaria:<\/strong> Patients with these conditions often experience persistent, severe itching that is difficult to manage with standard anti-inflammatory treatments. IL-31 inhibition may provide significant relief.<\/li>\n\n\n\n
Systemic Pruritus Conditions:<\/strong> Chronic itch related to kidney or liver disease may also involve IL-31 pathways. Targeting this cytokine could improve quality of life for patients experiencing systemic pruritus.<\/li>\n\n\n\n
Driving Future Research:<\/strong> Understanding IL-31\u2019s role in diverse itch conditions encourages further exploration of targeted therapies, potentially leading to new treatment options across dermatology and internal medicine.<\/li>\n<\/ul>\n\n\n\n
In conclusion, targeting IL-31 holds promise beyond eczema, with potential applications in a variety of chronic itch conditions. Research in this area could lead to innovative therapies that improve comfort and quality of life for patients struggling with persistent itch across multiple disorders.<\/p>\n\n\n\n
Patient Selection and Monitoring<\/strong><\/h2>\n\n\n\n
IL-31-targeted therapies are not necessary for every patient with eczema. They are generally considered for moderate-to-severe cases, especially when chronic itch is the predominant and most distressing symptom. Patients whose flare-ups are mild or who respond well to conventional anti-inflammatory treatments may not require these specialised therapies.<\/p>\n\n\n\n
Dermatologists carefully assess each patient before starting treatment. Standardised scoring systems, such as the Eczema Area and Severity Index (EASI) or patient-reported itch scales, are often used to measure baseline itch severity and track improvements over time.<\/p>\n\n\n\n
Ongoing monitoring allows clinicians to evaluate both itch reduction and skin healing, ensuring the therapy is effective and adjusting treatment plans as needed. This personalised approach helps maximise benefits while minimising unnecessary exposure to new medications.<\/p>\n\n\n\n
The Role of the Dermatologist<\/strong><\/h2>\n\n\n\n<\/figure>\n\n\n\n
A skilled dermatologist is central to determining whether IL-31-targeted therapy is suitable for a patient. They evaluate disease severity, identify the most pressing symptoms particularly chronic itch and establish clear treatment goals tailored to the individual\u2019s needs.<\/p>\n\n\n\n
Dermatologists also consider the patient\u2019s overall health, previous treatment responses, and potential side effects when designing a personalised management plan. This ensures that IL-31-targeted therapy is used effectively and safely, alongside other treatments if necessary.<\/p>\n\n\n\n
For patients seeking specialised care, clinics focusing on eczema treatment in London offer access to advanced therapies, comprehensive monitoring, and personalised care plans. Working with an experienced dermatologist increases the likelihood of meaningful itch relief and improved quality of life.<\/p>\n\n\n\n
Long-Term Considerations<\/strong><\/h2>\n\n\n\n
Research into IL-31-targeted therapies is ongoing, particularly regarding their long-term effects and sustained benefits. Early clinical data suggest that these treatments can provide ongoing reductions in chronic itch for several months, improving sleep, daily comfort, and overall quality of life.<\/p>\n\n\n\n
However, continuous monitoring is essential to evaluate both efficacy and safety over extended periods. Dermatologists track patients for potential side effects, changes in response, or the need for adjustments in therapy.<\/p>\n\n\n\n
Understanding long-term outcomes will help guide how IL-31 inhibitors are incorporated into standard eczema care. This knowledge ensures that patients receive treatments that are not only effective in the short term but also safe and beneficial for ongoing management of chronic itch.<\/p>\n\n\n\n
Impact on Quality of Life<\/strong><\/h2>\n\n\n\n
Effectively reducing chronic itch can have a profound impact on a patient\u2019s quality of life. Improved itch control often leads to better sleep, increased focus during daily activities, and reduced stress or irritability. Patients frequently report a noticeable improvement in mood and emotional wellbeing when persistent scratching is alleviated.<\/p>\n\n\n\n
Beyond physical relief, managing chronic itch can enhance confidence, social interactions, and overall lifestyle. Being able to engage in work, hobbies, and social situations without constant discomfort allows patients to feel more in control of their condition.<\/p>\n\n\n\n
These holistic benefits are a key reason why IL-31-targeted therapies are regarded as a breakthrough in eczema management. By addressing the root cause of chronic itch, these treatments provide meaningful improvements that extend well beyond the skin.<\/p>\n\n\n\n
Future Research Directions<\/strong><\/h2>\n\n\n\n
Ongoing research is exploring ways to optimise IL-31-targeted therapies and expand their benefits. Studies are investigating combination approaches with other anti-inflammatory or systemic treatments, refining dosing schedules, and assessing long-term safety and effectiveness.<\/p>\n\n\n\n
Researchers are also examining whether targeting related itch-signalling pathways could provide additional relief for patients who do not fully respond to IL-31 inhibition alone. This could broaden treatment options for a wider range of chronic itch conditions beyond eczema, such as prurigo nodularis or certain forms of psoriasis.<\/p>\n\n\n\n
This continued innovation suggests a future in which chronic itch can be managed more effectively than ever before. By combining targeted therapies with personalised treatment plans, patients may finally achieve sustained relief, improved skin health, and a better quality of life.<\/p>\n\n\n\n
The Importance of Early Intervention<\/strong><\/h2>\n\n\n\n
Addressing chronic itch early is critical to prevent long-term complications, such as skin thickening, excoriations from persistent scratching, and secondary infections. Repeated scratching not only worsens eczema symptoms but can also damage the skin barrier, making the condition more difficult to manage over time and increasing the risk of flare-ups.<\/p>\n\n\n\n
Dermatologists emphasise proactive treatment strategies that combine conventional anti-inflammatory therapies with emerging IL-31-targeted treatments when appropriate. Early use of these therapies can help interrupt the itch-scratch cycle before it becomes entrenched, reducing both physical damage to the skin and the emotional distress associated with relentless itching.<\/p>\n\n\n\n
By taking action early, patients are more likely to maintain healthy skin, achieve better symptom control, and preserve overall quality of life. Early intervention empowers patients to manage their eczema more effectively, prevent long-term complications, and enjoy greater comfort in daily activities.<\/p>\n\n\n\n
Practical Advice for Patients<\/strong><\/h2>\n\n\n\n
If chronic itch is significantly impacting your daily life, it\u2019s important to discuss IL-31-targeted treatment options with your dermatologist. Understanding whether this therapy is appropriate for your condition can help you achieve better symptom control and improve overall comfort.<\/p>\n\n\n\n
In addition to exploring new treatments, practical steps such as monitoring triggers, maintaining a consistent skincare routine, and adhering carefully to prescribed medications all play a key role in managing eczema effectively. These strategies help reduce flare-ups and support the skin\u2019s natural healing processes.<\/p>\n\n\n\n
Accessing specialised clinics, particularly those with expertise in eczema care, ensures you benefit from the latest evidence-based therapies. Here, you can receive personalised guidance on IL-31 inhibition and other advanced treatments, helping you manage chronic itch more effectively and improve your quality of life.<\/p>\n\n\n\n
Looking Ahead<\/strong><\/h2>\n\n\n\n
The discovery of IL-31\u2019s central role in chronic itch marks a significant advancement in eczema care. By targeting the underlying mechanisms that drive persistent itching, IL-31-focused therapies offer new hope for patients who have long struggled with symptoms that were difficult to manage with conventional treatments.<\/p>\n\n\n\n
As research progresses, the future of eczema management may involve a personalised, multi-pronged approach. This could combine targeted itch therapies, such as IL-31 inhibitors, with anti-inflammatory treatments, moisturisers, and lifestyle strategies to address both the symptoms and root causes of the disease.<\/p>\n\n\n\n
Such integrated care has the potential to transform patient outcomes, offering sustained relief from itch, improved skin health, better sleep, and enhanced overall quality of life. By addressing chronic itch directly, these therapies pave the way for a more effective and patient-focused standard of care in eczema management.<\/p>\n\n\n\n
FAQs:<\/strong><\/h2>\n\n\n\n
1. What is IL-31 and why does it matter in eczema?<\/strong> IL-31 is a cytokine, a signalling protein in the immune system. In eczema, it activates nerves in the skin that cause chronic itch, even when inflammation is controlled.<\/p>\n\n\n\n
2. How does IL-31 cause chronic itch?<\/strong> IL-31 binds to receptors on sensory nerves in the skin, sending signals to the brain that trigger the urge to scratch. This can create an \u201citch-scratch cycle\u201d that worsens eczema over time.<\/p>\n\n\n\n
3. Can traditional eczema treatments control IL-31-related itch? <\/strong>Conventional treatments reduce inflammation and soothe the skin but often do not directly block IL-31. Many patients still experience persistent itch despite these therapies.<\/p>\n\n\n\n
4. What are IL-31-targeted therapies? <\/strong>These treatments, such as monoclonal antibodies, block IL-31 or its receptor. By doing so, they prevent itch signals from reaching the brain and reduce chronic itching at its source.<\/p>\n\n\n\n
5. How effective is nemolizumab? <\/strong>Nemolizumab is an IL-31 inhibitor that has been shown in clinical trials to reduce itch intensity, improve sleep, and enhance daily comfort in moderate-to-severe eczema.<\/p>\n\n\n\n
6. Are IL-31-targeted treatments safe? <\/strong>Most patients tolerate these therapies well. Common side effects are mild, including injection site reactions or transient infections. They specifically target itch pathways without broadly suppressing the immune system.<\/p>\n\n\n\n
7. Can IL-31 inhibitors be used with other eczema treatments?<\/strong> Yes. They are often combined with topical corticosteroids, calcineurin inhibitors, or systemic therapies to address both inflammation and chronic itch.<\/p>\n\n\n\n
8. Who is suitable for IL-31-targeted therapy?<\/strong> Patients with moderate-to-severe eczema where chronic itch is the main problem are the most likely candidates. Dermatologists assess each patient individually using severity scores and symptom reports.<\/p>\n\n\n\n
9. Can IL-31-targeted therapies help conditions other than eczema? <\/strong>Potentially, yes. IL-31 is involved in other chronic itch conditions such as prurigo nodularis, chronic urticaria, and itch related to kidney or liver disease.<\/p>\n\n\n\n
10. How quickly can patients expect relief from IL-31-targeted treatments? <\/strong>Many patients notice reductions in itch and improvements in sleep before significant changes in skin appearance, highlighting the direct effect on nerve-mediated itch.<\/p>\n\n\n\n
Final Thoughts: Advancing Eczema Care by Targeting IL-31<\/strong><\/h2>\n\n\n\n
Chronic itch is often the most distressing symptom of eczema, affecting sleep, daily comfort, and overall quality of life. Targeting IL-31 represents a major advancement in managing this persistent itch, providing relief at its source rather than just addressing visible inflammation. Therapies such as nemolizumab offer hope for patients who have struggled with conventional treatments, helping to break the itch-scratch cycle and improve long-term outcomes.<\/p>\n\n\n\n
![\"\"](\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/02\/LDC-2-1-1024x559.jpg\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/03\/imagess-3-1024x559.jpg\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/02\/Patient-Communication-and-Education-1024x559.jpg\")
<\/figure>\n\n\n\n